PD-L1 is a potential predictive biomarker for response to RM-1929 treatment in recurrent head and neck squamous cell carcinoma patients

Category Primary study
JournalJournal for ImmunoTherapy of Cancer
Year 2020
This article has no abstract
Epistemonikos ID: 9a3ad958e016db939a16eaaada1c8091488cea3c
First added on: Feb 12, 2025